DIFFUSE LARGE B CELL LYMPHOMA

This early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…

This study tests a personalized treatment where a child's own immune cells are modified in a lab to recognize and attack cancer cells that have a protein called CD19. It is for children and young adults with certain types of leukemia or lymphoma that have come back or not respond…

This study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. About 363 adults with these aggressive lymphomas will receive either the usual chemo or the usual chemo plus venetoclax. The goal is …

This study tests an experimental drug called selinexor in adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who have run out of standard treatments. The main goal is to see how many patients respond to the drug. About 244 participants will …

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers or disorders. About 43 participants will receive vo…

This study follows about 1,000 Chinese adults with diffuse large B-cell lymphoma (a type of blood cancer) to see how well the drug polatuzumab works in everyday medical practice. Researchers will measure how long the cancer stays under control and track side effects. The study in…

This phase 3 study tests whether a new drug combination (epcoritamab plus lenalidomide) works better than standard chemotherapy for adults with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 379 participants will receive either the new …

This phase 3 trial compares a new immunotherapy drug, epcoritamab, given as a shot under the skin, with standard chemotherapy for people with diffuse large B-cell lymphoma that has returned or stopped responding to at least one prior treatment. About 484 participants will be rand…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have returned or not responded to prior treatments. The drug delivers radiation directly to cancer cells. A…

This study tests a combination of two drugs, tafasitamab and lenalidomide, in adults with diffuse large B-cell lymphoma that has come back or not responded to previous treatments. Participants must have had 1 to 3 prior treatments and cannot receive high-dose chemotherapy with a …

This study tests whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can help people with aggressive B-cell non-Hodgkin lymphoma. About 30 adults with advanced stages of the disease are taking part. The main goal is to see how long the c…

This study tests whether a new drug called glofitamab, when added to chemotherapy, works better than the current standard treatment for people with diffuse large B-cell lymphoma that has returned or stopped responding to prior therapy. About 270 adults will be randomly assigned t…

This early-stage study tests a new drug called ABBV-525 in people with B-cell cancers like lymphoma and leukemia. The goal is to find a safe dose and see if it can shrink tumors. About 78 adults will take the drug by mouth at different doses over several months.

This study looks at a new way of giving standard chemotherapy (R-CHOP) to older adults aged 75 and up with diffuse large B-cell lymphoma. The goal is to see if splitting the doses makes treatment easier to tolerate while still being effective. About 27 participants will receive t…

This early-stage study tests a new drug called GNC-038 in 12 people with diffuse large B-cell lymphoma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. It is a first step to see…

This study tests adding a drug called selinexor to the standard chemotherapy RCHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than RCHOP alone. About 43 adults with advanced or returning lymphoma are ta…

This study tests whether using ctDNA blood tests and PET scans can help doctors tailor treatment for people with diffuse large B-cell lymphoma (DLBCL). About 260 participants will receive standard chemotherapy (R-CHOP) plus or minus a targeted drug (acalabrutinib) based on their …

This study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. The goal is to find the best dose and see if the combination is safe and works better than standard treatment alone. Ab…

This study tests an investigational drug called epcoritamab, given alone or with other standard treatments, in about 543 people with B-cell non-Hodgkin lymphoma. The goal is to find the best dose and see how well it shrinks tumors. Participants receive active treatment; no one ge…

This study tests a new drug called epcoritamab (given as a shot under the skin) against standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 72 adults in China who cannot have a stem cell transplant will …

This study tests whether adding the drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a certain type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). About 611 adults aged 18 to 75 are participating. The main goal is to see if the combination delay…

This study looks at whether giving vitamin D supplements to cancer patients who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 adults with certain types of lymphoma or leukemia are taking part. Researchers are comparing those who …

This study tests a drug called epcoritamab, given alone or with another drug (lenalidomide), in elderly patients with a type of lymphoma (DLBCL) who cannot receive standard chemotherapy. The goal is to see if the treatment can shrink or eliminate the cancer. About 111 participant…

This study looks at whether adding the drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). About 450 adults with untreated DLBCL will receive one round of standard chemo, then two-thirds will …

This study tests a new treatment called rapcabtagene autoleucel (YTB323) for several types of blood cancer, including chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. About 217 adults will receive this ther…

This study tests a new drug called MT-2111 for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has returned or not improved after at least two prior treatments. The first part of the study finds a safe dose, and the second part checks if the d…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This study tests whether adding a drug called E7777 before standard CAR-T cell therapy can help people with relapsed or hard-to-treat large B-cell lymphoma. About 30 adults will receive E7777 followed by chemotherapy and an approved CAR-T product. The goal is to find the safest d…

This study is for people with diffuse large B-cell lymphoma (DLBCL) that has returned or not responded to at least two prior treatments. It tests whether adding the drug brentuximab vedotin to two standard drugs (lenalidomide and rituximab) works better than the two drugs alone. …

This study tests a new drug combination for people with aggressive types of B-cell lymphoma that haven't been treated yet. The treatment adds a targeted drug called polatuzumab vedotin to standard chemotherapy. The goal is to see if this combo can make the cancer disappear comple…

This early-stage trial tests a new drug, zanubrutinib, added to a standard chemotherapy cocktail (R-PolaCHP) for people newly diagnosed with diffuse large B-cell lymphoma. The main goal is to find the safest dose and understand side effects. About 38 adults with this type of bloo…

This study tests a combination of two drugs, copanlisib and venetoclax, in people with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 48 adults will take pa…

This study tests an experimental drug called epcoritamab in Japanese adults whose B-cell lymphoma has come back or not responded to treatment. The trial has two parts: first, finding a safe dose, and second, checking how well the drug works alone or with other treatments. About 7…

This study tests whether adding the targeted drug polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the current standard (R-CHOP) for people with untreated diffuse large B-cell lymphoma. About 1000 participants will receive either the new combination or the s…

This study tests the safety and effectiveness of a drug called tafasitamab, given alone or combined with other medicines (lenalidomide, parsaclisib, or R-CHOP), in Japanese adults with Non-Hodgkin lymphoma. About 72 participants with relapsed or untreated disease will receive dif…

This study tests a modified dosing schedule of the drug tafasitamab combined with lenalidomide in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have had 1 to 3 prior treatments and cannot have a stem cell transplant. The main goal is to check the sa…

This study tests an experimental drug called DZD8586 in 59 adults with diffuse large B-cell lymphoma that has returned or stopped responding to prior treatments. The goal is to see if the drug can shrink tumors and to understand its side effects and how the body processes it. Par…

This study tests a mix of targeted drugs (rituximab, lenalidomide, acalabrutinib, tafasitamab) given before and with standard chemotherapy for people with a certain type of newly diagnosed lymphoma (DLBCL). The goal is to see if this combination can shrink or eliminate tumors bet…

This early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with Richter's transformation or certain non-Hodgkin lymphomas. The goal is to find the safest dose and see how well the drugs work together. About 27 adults will take part, and the study…

This study looks at whether giving a lower dose of radiation to people with diffuse large B-cell lymphoma (a type of blood cancer) can still keep the cancer from coming back while causing fewer side effects. About 241 participants who had a clear PET scan after chemotherapy will …

This study tests whether adding two drugs, tafasitamab and lenalidomide, to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called DLBCL. About 900 patients with high-risk, newly diagnosed disease are taking part. The goal is to see if the new com…

This study looks at whether a blood test can quickly detect leftover cancer DNA in people treated with CAR-T cells for diffuse large B-cell lymphoma. About 40 adults will give a blood sample a week after their CAR-T infusion, and researchers aim to report results within three wee…

This study teaches doctors special communication skills to help lymphoma patients move from active treatment into survivorship. About 314 patients with Hodgkin's or Diffuse Large B-cell Lymphoma and their doctors took part. The goal is to see if better doctor-patient conversation…

This study tests a new nanochip technology to see if it can better monitor how well treatment is working and detect if lymphoma comes back in people with diffuse large B-cell lymphoma. About 73 participants will provide blood samples during their standard chemotherapy. The goal i…

This study follows about 50 people who have already received an experimental CAR T cell therapy for certain types of lymphoma. The goal is to track any long-term side effects and survival for up to 15 years after treatment. No new study drug is given, but participants may receive…

This study collects white blood cells from people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are used to create a personalized therapy called CAR T-cells, which may be given later. The procedure, called leukapheresis, takes 4-6…